1. Able to provide informed consent, willing and able to comply with the scheduled visits, examinations, and other procedural requirements of the treatment.
2. Aged 18-75 years (inclusive) at the time of signing the informed consent form, with no restriction on sex.
3. ECOG score of 0 or 1.
4. Patients with histologically confirmed locally advanced or metastatic non-squamous NSCLC.
5. Participants with HER2 overexpression confirmed by a central laboratory.
6. Have not previously received systemic antitumor therapy for locally advanced or metastatic NSCLC.
You may not be if
1. Participants with untreated or active metastasis of central nervous system (CNS) tumors, or a history of meningeal metastasis or current meningeal metastasis.
2. Previous or current with other malignancies.
3. Prior antitumor toxicity and/or complications have not recovered to NCI-CTCAE ≤ Grade 1.
4. Currently participating in another clinical study, or the interval between the start of study treatment and the end of the previous clinical study is less than specified period.
5. Participants with active or previous autoimmune diseases.
6. Participants with uncontrolled or severe cardiovascular diseases.
7. Participants with active hepatitis B or hepatitis C.